Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania Show more

Location: 125 Strafford Avenue, Wayne, PA, 19087, United States | Website: https://palvellatx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

1.123B

52 Wk Range

$11.17 - $104.91

Previous Close

$94.87

Open

$95.23

Volume

93,999

Day Range

$94.50 - $101.19

Enterprise Value

1.101B

Cash

63.57M

Avg Qtr Burn

-6.368M

Insider Ownership

21.36%

Institutional Own.

73.61%

Qtr Updated

09/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.